Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter adjusted operating profit of £1.75 billion, up 10% at the actual exchange rate (AER) and up 21% at the constant exchange rate (CER). The company’s RSV vaccine, Arexvy, hit £1.2 billion in sales in 2023 and £529 million in the fourth quarter. Approximately 6 million of the 83 million U.S. adults aged 60 and older at risk have been vaccinated with Arexvy. The company reported sales of $10 billion (£8.1 billion), beating the consensus of $9.61 b
China's largest vaccines company Zhifei will pay British drugmaker GSK 2.5 billion pounds ($3.05 billion pound) for the exclusive rights to distribute GSK's shingles vaccine in the world's No.2 pharmaceuticals market. The deal is one of a series of moves by western pharmaceutical firms to seize a bigger share of China's market, including announcements from companies such as AstraZeneca. The deal with Zhifei is part of its efforts to reach more than 4 billion pounds ($4.88 billion) in sales by 2026, GSK said.
In January 2022, CSK became India's first unicorn sports enterprise when the BCCI sold its two franchises of Lucknow to RPSG Group and Ahmedabad to Capri Global for Rs 7,090 crore and Rs 5,625 crore, respectively.
At the end of the latest market close, GSK plc (GSK) was valued at $30.11. In that particular session, Stock kicked-off at the price of $30.19 while reaching the peak value of $30.42 and lowest value recorded on the day was $30.04. The stock current value is $30.20.Recently in News on September 22,
Let’s start up with the current stock price of GSK plc (GSK), which is $30.33 to be very precise. The Stock rose vividly during the last session to $29.695 after opening rate of $29.46 while the lowest price it went was recorded $29.38 before closing at $29.43.Recently in News on September 22, 202